Jupiter Neurosciences, Inc. (JUNS) Stock

About Jupiter Neurosciences, Inc.

Jupiter Neurosciences, Inc. is a pharmaceutical company engaged in clinical-stage research and development. Its primary focus is on advancing a resveratrol-based platform product, with the main objective of addressing neuro-inflammation. The company's pipeline includes several drug candidates: JNS101 is undergoing Phase II trials for Friedreich's Ataxia, a rare neurological disorder that damages the nervous system and causes mobility issues. Also in Phase II, JNS102 is being developed for mucopolysaccharidosis Type I, JNS107 for MELAS Syndrome, and JNS108 for mild cognitive impairment and early Alzheimer's disease. Furthermore, the company is progressing JNS109 for amyotrophic lateral sclerosis, JNS110 for traumatic brain injury and concussion, and JNS120 as a treatment for COVID-19. Founded in 2016, the company, formerly known as Jupiter Orphan Therapeutics, Inc., adopted its current name in August 2021 and is headquartered in Jupiter, Florida.

Jupiter Neurosciences, Inc. is led by CEO Christer Rosen, publicly traded since 2022.

Jupiter Neurosciences, Inc. (JUNS) stock trades at $0.11 with a market capitalization of $4.16M. The stock is valued at a price-to-earnings (P/E) ratio of -0.45, price-to-book of -1.53, price-to-sales of 108.74. Over the past 52 weeks the stock has ranged between $0.11 and $1.84, and currently trades 94.0% below its 52-week high.

On profitability, Jupiter Neurosciences, Inc. generates a return on equity (ROE) of 450.00% — well above the market average, a sign of a high-quality business, return on capital employed of 335.33%, an operating margin of -230.76%, a net profit margin of -226.91%.

Official website: jupiterneurosciences.com